Abstract

The cereblon modulating agents (CMs) including lenalidomide, pomalidomide and CC-220 repurpose the Cul4-RBX1-DDB1-CRBN (CRL4CRBN) E3 ubiquitin ligase complex to induce the degradation of specific neomorphic substrates via polyubiquitination in conjunction with E2 ubiquitin-conjugating enzymes, which have until now remained elusive. Here we show that the ubiquitin-conjugating enzymes UBE2G1 and UBE2D3 cooperatively promote the K48-linked polyubiquitination of CRL4CRBN neomorphic substrates via a sequential ubiquitination mechanism. Blockade of UBE2G1 diminishes the ubiquitination and degradation of neomorphic substrates, and consequent antitumor activities elicited by all tested CMs. For example, UBE2G1 inactivation significantly attenuated the degradation of myeloma survival factors IKZF1 and IKZF3 induced by lenalidomide and pomalidomide, hence conferring drug resistance. UBE2G1-deficient myeloma cells, however, remained sensitive to a more potent IKZF1/3 degrader CC-220. Collectively, it will be of fundamental interest to explore if loss of UBE2G1 activity is linked to clinical resistance to drugs that hijack the CRL4CRBN to eliminate disease-driving proteins.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files

Article and author information

Author details

  1. Gang Lu

    PH TCoE, Celgene, San Diego, United States
    For correspondence
    glu@celgene.com
    Competing interests
    Gang Lu, Employee of Celgene.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2138-1522
  2. Stephanie Weng

    PH TCoE, Celgene, San Diego, United States
    Competing interests
    Stephanie Weng, Employee of Celgene.
  3. Mary Matyskiela

    Structral and Chemical Biology, Celgene, San Diego, United States
    Competing interests
    Mary Matyskiela, Employee of Celgene.
  4. Xinde Zheng

    PH TCoE, Celgene, San Diego, United States
    Competing interests
    Xinde Zheng, Employee of Celgene.
  5. Wei Fang

    Structral and Chemical Biology, Celgene, San Diego, United States
    Competing interests
    Wei Fang, Employee of Celgene.
  6. Scott Wood

    PH TCoE, Celgene, San Diego, United States
    Competing interests
    Scott Wood, Employee of Celgene.
  7. Christine Surka

    PH TCoE, Celgene, San Diego, United States
    Competing interests
    Christine Surka, Employee of Celgene.
  8. Reina Mizukoshi

    PH TCoE, Celgene, San Diego, United States
    Competing interests
    Reina Mizukoshi, Employee of Celgene.
  9. Chin-Chun Lu

    PH TCoE, Celgene, San Diego, United States
    Competing interests
    Chin-Chun Lu, Employee of Celgene.
  10. Derek Mendy

    PH TCoE, Celgene, San Diego, United States
    Competing interests
    Derek Mendy, Employee of Celgene.
  11. In Sock Jang

    Research Analytics, Celgene, San Diego, United States
    Competing interests
    In Sock Jang, Employee of Celgene.
  12. Kai Wang

    Research Analytics, Celgene, San Diego, United States
    Competing interests
    Kai Wang, Employee of Celgene.
  13. Mathieu Marella

    NCD - Exploratory Toxicology, Celgene, San Diego, United States
    Competing interests
    Mathieu Marella, Employee of Celgene.
  14. Suzana Couto

    NCD - Exploratory Toxicology, Celgene, San Diego, United States
    Competing interests
    Suzana Couto, Employee of Celgene.
  15. Brian Cathers

    PH TCoE, Celgene, San Diego, United States
    Competing interests
    Brian Cathers, Employee of Celgene.
  16. James Carmichael

    PH TCoE, Celgene, San Diego, United States
    Competing interests
    James Carmichael, Employee of Celgene.
  17. Philip Chamberlain

    Structral and Chemical Biology, Celgene, San Diego, United States
    Competing interests
    Philip Chamberlain, Employee of Celgene.
  18. Mark Rolfe

    PH TCoE, Celgene, San Diego, United States
    Competing interests
    Mark Rolfe, Employee of Celgene.

Funding

No external funding was received for this work

Reviewing Editor

  1. Wade Harper, Harvard Medical School, United States

Version history

  1. Received: August 10, 2018
  2. Accepted: September 19, 2018
  3. Accepted Manuscript published: September 20, 2018 (version 1)
  4. Version of Record published: October 12, 2018 (version 2)

Copyright

© 2018, Lu et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 4,798
    views
  • 810
    downloads
  • 54
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Gang Lu
  2. Stephanie Weng
  3. Mary Matyskiela
  4. Xinde Zheng
  5. Wei Fang
  6. Scott Wood
  7. Christine Surka
  8. Reina Mizukoshi
  9. Chin-Chun Lu
  10. Derek Mendy
  11. In Sock Jang
  12. Kai Wang
  13. Mathieu Marella
  14. Suzana Couto
  15. Brian Cathers
  16. James Carmichael
  17. Philip Chamberlain
  18. Mark Rolfe
(2018)
UBE2G1 governs the destruction of cereblon neomorphic substrates
eLife 7:e40958.
https://doi.org/10.7554/eLife.40958

Share this article

https://doi.org/10.7554/eLife.40958

Further reading

    1. Biochemistry and Chemical Biology
    2. Cell Biology
    Natalia Dolgova, Eva-Maria E Uhlemann ... Oleg Y Dmitriev
    Research Article

    Mediator of ERBB2-driven Cell Motility 1 (MEMO1) is an evolutionary conserved protein implicated in many biological processes; however, its primary molecular function remains unknown. Importantly, MEMO1 is overexpressed in many types of cancer and was shown to modulate breast cancer metastasis through altered cell motility. To better understand the function of MEMO1 in cancer cells, we analyzed genetic interactions of MEMO1 using gene essentiality data from 1028 cancer cell lines and found multiple iron-related genes exhibiting genetic relationships with MEMO1. We experimentally confirmed several interactions between MEMO1 and iron-related proteins in living cells, most notably, transferrin receptor 2 (TFR2), mitoferrin-2 (SLC25A28), and the global iron response regulator IRP1 (ACO1). These interactions indicate that cells with high MEMO1 expression levels are hypersensitive to the disruptions in iron distribution. Our data also indicate that MEMO1 is involved in ferroptosis and is linked to iron supply to mitochondria. We have found that purified MEMO1 binds iron with high affinity under redox conditions mimicking intracellular environment and solved MEMO1 structures in complex with iron and copper. Our work reveals that the iron coordination mode in MEMO1 is very similar to that of iron-containing extradiol dioxygenases, which also display a similar structural fold. We conclude that MEMO1 is an iron-binding protein that modulates iron homeostasis in cancer cells.

    1. Biochemistry and Chemical Biology
    2. Structural Biology and Molecular Biophysics
    Isabelle Petit-Hartlein, Annelise Vermot ... Franck Fieschi
    Research Article

    NADPH oxidases (NOX) are transmembrane proteins, widely spread in eukaryotes and prokaryotes, that produce reactive oxygen species (ROS). Eukaryotes use the ROS products for innate immune defense and signaling in critical (patho)physiological processes. Despite the recent structures of human NOX isoforms, the activation of electron transfer remains incompletely understood. SpNOX, a homolog from Streptococcus pneumoniae, can serves as a robust model for exploring electron transfers in the NOX family thanks to its constitutive activity. Crystal structures of SpNOX full-length and dehydrogenase (DH) domain constructs are revealed here. The isolated DH domain acts as a flavin reductase, and both constructs use either NADPH or NADH as substrate. Our findings suggest that hydride transfer from NAD(P)H to FAD is the rate-limiting step in electron transfer. We identify significance of F397 in nicotinamide access to flavin isoalloxazine and confirm flavin binding contributions from both DH and Transmembrane (TM) domains. Comparison with related enzymes suggests that distal access to heme may influence the final electron acceptor, while the relative position of DH and TM does not necessarily correlate with activity, contrary to previous suggestions. It rather suggests requirement of an internal rearrangement, within the DH domain, to switch from a resting to an active state. Thus, SpNOX appears to be a good model of active NOX2, which allows us to propose an explanation for NOX2’s requirement for activation.